The BCR–ABL fusion gene in chronic myelogenous leukemia (CML) acts as an antiapoptotic gene, activating various signaling pathways such as PI3K/AKT, JAK/STAT, RAS, and NF‐κB.176. The gene discussed is NFKB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.